• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    December 14, 2023 - FDA Warns Nine Manufacturers, Distributors of Unapproved Antimicrobials for Animals

    12/14/23 9:00:20 AM ET
    $CHWY
    Catalog/Specialty Distribution
    Consumer Discretionary
    Get the next $CHWY alert in real time by email
    For Immediate Release:
    December 14, 2023

    Today, the U.S. Food and Drug Administration is announcing the issuance of nine warning letters to manufacturers and distributors of unapproved and misbranded antimicrobial animal drugs for violations of federal law. The agency is concerned because these products contain antimicrobials that are important in human medicine and using them without medical oversight contributes to the development of antimicrobial resistance. Antimicrobial resistance happens when microorganisms like bacteria become resistant to the antimicrobials that are designed to kill them. 

    The marketed products are not the subject of a New Animal Drug Application, nor are they Conditionally Approved or on the Index of Legally Marketed Unapproved New Animal Drugs for Minor Species – the main legal pathways for animal drugs to reach the marketplace. Therefore, the FDA has not verified their safety or effectiveness as part of the animal drug review process or facility inspections. 

    The animal products referenced in the warning letters are marketed and labeled for minor species such as aquarium fish and pet birds. They contain antimicrobials that are important in human medicine, such as amoxicillin, penicillin, tetracycline, and erythromycin, and are being illegally marketed over the counter. 

    “These unapproved animal drugs pose a two-fold risk to public health,” said Tracey Forfa, J.D., director of the FDA’s Center for Veterinary Medicine. “First, these products haven’t been through the FDA drug review process, and we don’t know whether they’re safe or effective, or even contain what the label states. Second, inappropriate use of medically important antimicrobials contributes to the development of antimicrobial resistance, which affects both human and animal health.”  

    All approved animal drugs containing these antimicrobials are only legally available by prescription from a licensed veterinarian. Veterinarians use their specialized training and experience to properly diagnose and treat animal health issues. Providing animals with the appropriate drug is more likely to effectively resolve infections and reduce the need for extended treatment with antimicrobials. Judicious use of antimicrobials reduces the risk of developing antimicrobial resistance and helps ensure better health outcomes.

    Additionally, it’s important to note that using unapproved animal drugs in humans can be especially dangerous because these products have not been evaluated by the FDA, and because many animal drugs are not identical to similar products approved for use in people. Self-diagnosis and treatment with unapproved animal antimicrobials could delay effective treatment, allowing infections to become more severe and/or more resistant to antimicrobials. 

    Anyone currently using or administering the products included in these warning letters should safely dispose of them. Animal owners or caretakers should consult a licensed veterinarian, and people should consult a licensed health care provider, to obtain an accurate diagnosis and appropriate treatment. Consumers, veterinarians, and health care providers are encouraged to report human and animal adverse events associated with these products to the FDA’s Center for Veterinary Medicine: How to Report Animal Drug and Device Side Effects and Product Problems. 

    The following companies received warning letters:

    • American Aquarium Products
    • Aquanest Biotic
    • Aquarium Pharmacy LLC
    • California Veterinary Supply
    • Chewy Inc.
    • Kraft Drug
    • Midland Veterinary Services LLC
    • Silver Lease LLC
    • Valley Veterinary Clinic LTD

    The FDA has asked the companies to respond to the warning letters within 15 days of receipt to state how they will address the violations cited in the warning letters. Failure to address the violations promptly may result in the FDA’s legal action, including product seizure and/or a court order requiring a company to stop manufacturing and distributing unapproved products.

    The FDA will continue to monitor the marketplace and take necessary steps to protect human and animal health against companies selling unapproved animal drugs that can put people and animals at risk.

     

    Related Information

    Related Information
    • How to Report Animal Drug and Device Side Effects and Product Problems
    • FDA’s Concerns About Unapproved Animal Drugs
    • Ornamental Fish Drugs and You
    • CVM: Antimicrobial Resistance

    ###

    Boilerplate

    The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products.


    Inquiries

    Media:
    Veronika Pfaeffle
    301-310-2576
    Consumer:
    888-INFO-FDA

     
    Get the next $CHWY alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CHWY

    DatePrice TargetRatingAnalyst
    9/25/2025$48.00Neutral → Buy
    MoffettNathanson
    9/11/2025$47.00Neutral → Buy
    Seaport Research Partners
    9/11/2025$45.00Hold → Buy
    Deutsche Bank
    9/8/2025$50.00Neutral → Outperform
    Mizuho
    7/10/2025Mkt Outperform
    Citizens JMP
    6/9/2025$47.00Outperform → Neutral
    Mizuho
    6/5/2025$43.00Buy → Hold
    Jefferies
    3/24/2025Neutral
    Seaport Research Partners
    More analyst ratings

    $CHWY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Chewy upgraded by MoffettNathanson with a new price target

    MoffettNathanson upgraded Chewy from Neutral to Buy and set a new price target of $48.00

    9/25/25 8:21:50 AM ET
    $CHWY
    Catalog/Specialty Distribution
    Consumer Discretionary

    Chewy upgraded by Seaport Research Partners with a new price target

    Seaport Research Partners upgraded Chewy from Neutral to Buy and set a new price target of $47.00

    9/11/25 8:35:47 AM ET
    $CHWY
    Catalog/Specialty Distribution
    Consumer Discretionary

    Chewy upgraded by Deutsche Bank with a new price target

    Deutsche Bank upgraded Chewy from Hold to Buy and set a new price target of $45.00

    9/11/25 8:34:30 AM ET
    $CHWY
    Catalog/Specialty Distribution
    Consumer Discretionary

    $CHWY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Star James A bought $249,519 worth of shares (12,242 units at $20.38), increasing direct ownership by 9% to 141,790 units (SEC Form 4)

    4 - Chewy, Inc. (0001766502) (Issuer)

    12/18/23 4:09:39 PM ET
    $CHWY
    Catalog/Specialty Distribution
    Consumer Discretionary

    Star James A bought $300,992 worth of shares (15,353 units at $19.60), increasing direct ownership by 13% to 129,548 units (SEC Form 4)

    4 - Chewy, Inc. (0001766502) (Issuer)

    12/14/23 4:10:59 PM ET
    $CHWY
    Catalog/Specialty Distribution
    Consumer Discretionary

    $CHWY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 14, 2023 - FDA Warns Nine Manufacturers, Distributors of Unapproved Antimicrobials for Animals

    For Immediate Release: December 14, 2023 Today, the U.S. Food and Drug Administration is announcing the issuance of nine warning letters to manufacturers and distributors of unapproved and misbranded antimicrobial animal drugs for violations of federal law. The agency is concerned because these products contain antimicrobials that are important in human medicine and using them without medical oversight contribut

    12/14/23 9:00:20 AM ET
    $CHWY
    Catalog/Specialty Distribution
    Consumer Discretionary

    $CHWY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $CHWY
    SEC Filings

    View All

    $CHWY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Chief Technology Officer Mehta Satish sold $1,622,278 worth of shares (46,765 units at $34.69), decreasing direct ownership by 17% to 229,702 units (SEC Form 4)

    4 - Chewy, Inc. (0001766502) (Issuer)

    9/17/25 4:02:09 PM ET
    $CHWY
    Catalog/Specialty Distribution
    Consumer Discretionary

    Chief Executive Officer Singh Sumit sold $1,203,030 worth of shares (33,821 units at $35.57), decreasing direct ownership by 5% to 540,406 units (SEC Form 4)

    4 - Chewy, Inc. (0001766502) (Issuer)

    8/6/25 5:06:54 PM ET
    $CHWY
    Catalog/Specialty Distribution
    Consumer Discretionary

    Chief Accounting Officer Billings William G. sold $716,461 worth of shares (20,142 units at $35.57), decreasing direct ownership by 41% to 29,464 units (SEC Form 4)

    4 - Chewy, Inc. (0001766502) (Issuer)

    8/6/25 5:03:42 PM ET
    $CHWY
    Catalog/Specialty Distribution
    Consumer Discretionary

    SEC Form 10-Q filed by Chewy Inc.

    10-Q - Chewy, Inc. (0001766502) (Filer)

    9/10/25 7:29:02 AM ET
    $CHWY
    Catalog/Specialty Distribution
    Consumer Discretionary

    Chewy Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Chewy, Inc. (0001766502) (Filer)

    9/10/25 7:03:43 AM ET
    $CHWY
    Catalog/Specialty Distribution
    Consumer Discretionary

    Amendment: SEC Form SCHEDULE 13G/A filed by Chewy Inc.

    SCHEDULE 13G/A - Chewy, Inc. (0001766502) (Subject)

    8/14/25 4:20:25 PM ET
    $CHWY
    Catalog/Specialty Distribution
    Consumer Discretionary

    Chewy Launches "Get Real™," A New Healthy Fresh Food for Dogs

    Real, simple food, packed with fresh ingredients, for healthy pets Chewy, Inc. (NYSE:CHWY) ("Chewy"), a trusted destination for pet parents and partners everywhere, today announced the launch of Get Real TM, a new line of minimally processed, fresh dog food available only at Chewy. The high-quality food comes in three different pup-approved recipes including Chicken & Brussels Sprouts, Beef & Sweet Potato and Turkey & Cranberry – all available as both full meals and meal toppers, made with 10 or fewer ingredients plus vitamins and minerals. Consumer demand for fresh dog food has never been higher; in fact, the fresh segment's growth is outpacing all other companion pet food categories.

    9/10/25 10:00:00 AM ET
    $CHWY
    Catalog/Specialty Distribution
    Consumer Discretionary

    Chewy Announces Second Quarter 2025 Financial Results

    Chewy, Inc. (NYSE:CHWY) ("Chewy"), a trusted destination for pet parents and partners everywhere, has released its financial results for the second quarter of fiscal year 2025 ended August 3, 2025. Fiscal Q2 2025 Highlights: Net sales of $3.10 billion increased 8.6 percent year over year Gross margin of 30.4 percent increased 90 basis points year over year Net income of $62.0 million, including share-based compensation expense and related taxes of $79.1 million Net margin of 2.0 percent decreased 850 basis points year over year(2) Basic earnings per share of $0.15, a decrease of $0.55 year over year(2) Diluted earnings per share of $0.14, a decrease of $0.54 year over ye

    9/10/25 7:05:00 AM ET
    $CHWY
    Catalog/Specialty Distribution
    Consumer Discretionary

    Chewy Announces Fiscal Second Quarter 2025 Financial Results Conference Call

    Chewy, Inc. (NYSE:CHWY) ("Chewy"), a trusted destination for pet parents and partners everywhere, announced today that it will report fiscal second quarter 2025 financial results before the market opens on Wednesday, September 10, 2025. Management will host a conference call and webcast to discuss the company's financial results at 8:00 am ET. To access the conference call by phone, please visit this link for registration (Phone Registration Link) to be provided with dial in details, including a unique PIN to access the conference call. To avoid delays, we encourage participants to register in advance or at a minimum 15 minutes before the start of the call. A live audio webcast can be a

    8/20/25 7:30:00 AM ET
    $CHWY
    Catalog/Specialty Distribution
    Consumer Discretionary

    $CHWY
    Leadership Updates

    Live Leadership Updates

    View All

    Chewy Set to Join S&P MidCap 400

    NEW YORK, Nov. 1, 2024 /PRNewswire/ -- Chewy Inc. (NYSE: CHWY) will replace Stericycle Inc. (NASD: SRCL) in the S&P MidCap 400 effective prior to the opening of trading on Wednesday, November 6. S&P 500 constituent Waste Management Inc. (NYSE:WM) is acquiring Stericycle in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector November 6, 2024 S&P MidCap 400 Addition Chewy CHWY Consumer Discretionary November 6, 2024 S&P MidCap 400 Deletion Stericycle SRCL Industrial For more information about

    11/1/24 7:11:00 PM ET
    $CHWY
    $SPGI
    $SRCL
    Catalog/Specialty Distribution
    Consumer Discretionary
    Finance: Consumer Services
    Finance

    Chewy Appoints Mark Eamer as Chief Marketing Officer

    Seasoned Leader to Spearhead Continued Expansion of Chewy's Marketing and Customer Engagement Capabilities Chewy, Inc. ("Chewy") (NYSE:CHWY), a leading online destination for pet parents and partners, announced today the appointment of Mark Eamer as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210930005601/en/Chewy Appoints Mark Eamer as Chief Marketing Officer (Photo: Business Wire) As CMO, Mark will spearhead the continued expansion of Chewy's Marketing and Customer Engagement capabilities, with ownership of the company's marketing strategy, partnerships and analytics, including full funnel cus

    9/30/21 9:00:00 AM ET
    $CHWY
    Catalog/Specialty Distribution
    Consumer Discretionary

    GameStop Announces Additional Board Refreshment to Accelerate Transformation

    Aligns with Ryan Cohen of RC Ventures on the Immediate Appointment of Three New Directors with Significant E-Commerce and Technology Experience Confirms the Board’s Commitment to Supporting GameStop’s Pursuit of Growth and Market Leadership GRAPEVINE, Texas, Jan. 11, 2021 (GLOBE NEWSWIRE) -- GameStop Corp. (NYSE: GME) (“GameStop” or the “Company”) today announced that it has entered into an agreement with RC Ventures LLC (“RC Ventures”) that will advance the refreshment of the Company’s Board of Directors (the “Board”). RC Ventures, which is one of the Company’s largest stockholders, is managed by Ryan Cohen. The agreement provides for the immediate appointment of three new directors –

    1/11/21 7:30:00 AM ET
    $CHWY
    $GME
    Catalog/Specialty Distribution
    Consumer Discretionary
    Electronics Distribution

    $CHWY
    Financials

    Live finance-specific insights

    View All

    $CHWY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Chewy Announces Second Quarter 2025 Financial Results

    Chewy, Inc. (NYSE:CHWY) ("Chewy"), a trusted destination for pet parents and partners everywhere, has released its financial results for the second quarter of fiscal year 2025 ended August 3, 2025. Fiscal Q2 2025 Highlights: Net sales of $3.10 billion increased 8.6 percent year over year Gross margin of 30.4 percent increased 90 basis points year over year Net income of $62.0 million, including share-based compensation expense and related taxes of $79.1 million Net margin of 2.0 percent decreased 850 basis points year over year(2) Basic earnings per share of $0.15, a decrease of $0.55 year over year(2) Diluted earnings per share of $0.14, a decrease of $0.54 year over ye

    9/10/25 7:05:00 AM ET
    $CHWY
    Catalog/Specialty Distribution
    Consumer Discretionary

    Chewy Announces Fiscal Second Quarter 2025 Financial Results Conference Call

    Chewy, Inc. (NYSE:CHWY) ("Chewy"), a trusted destination for pet parents and partners everywhere, announced today that it will report fiscal second quarter 2025 financial results before the market opens on Wednesday, September 10, 2025. Management will host a conference call and webcast to discuss the company's financial results at 8:00 am ET. To access the conference call by phone, please visit this link for registration (Phone Registration Link) to be provided with dial in details, including a unique PIN to access the conference call. To avoid delays, we encourage participants to register in advance or at a minimum 15 minutes before the start of the call. A live audio webcast can be a

    8/20/25 7:30:00 AM ET
    $CHWY
    Catalog/Specialty Distribution
    Consumer Discretionary

    Chewy Announces First Quarter 2025 Financial Results

    Chewy, Inc. (NYSE:CHWY) ("Chewy"), a trusted destination for pet parents and partners everywhere, has released its financial results for the first quarter of fiscal year 2025 ended May 4, 2025. Fiscal Q1 2025 Highlights: Net sales of $3.12 billion increased 8.3 percent year over year Gross margin of 29.6 percent decreased 10 basis points year over year Net income of $62.4 million, including share-based compensation expense and related taxes of $78.0 million Net margin of 2.0 percent decreased 30 basis points year over year Basic earnings per share of $0.15, consistent year over year Diluted earnings per share of $0.15, consistent year over year Adjusted EBITDA(1) of $

    6/11/25 7:05:00 AM ET
    $CHWY
    Catalog/Specialty Distribution
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Chewy Inc.

    SC 13G/A - Chewy, Inc. (0001766502) (Subject)

    11/12/24 2:29:11 PM ET
    $CHWY
    Catalog/Specialty Distribution
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Chewy Inc.

    SC 13G/A - Chewy, Inc. (0001766502) (Subject)

    11/6/24 4:39:56 PM ET
    $CHWY
    Catalog/Specialty Distribution
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Chewy Inc.

    SC 13G/A - Chewy, Inc. (0001766502) (Subject)

    11/4/24 11:23:07 AM ET
    $CHWY
    Catalog/Specialty Distribution
    Consumer Discretionary